Video

Dr. Lynch on the Goals of Bristol-Myers Squibb

Thomas Lynch, Jr, MD, Vice President and Chief Scientific Officer at Bristol-Myers Squibb, discusses goals at Bristol-Myers Squibb.

Thomas Lynch, Jr, MD, Vice President and Chief Scientific Officer at Bristol-Myers Squibb, discusses the goals of Bristol-Myers Squibb.

Lynch believes that physicians are motivated by 2 things—the desire to help patients and the sense of mission of the hospital, doctors, and nurses. These caregivers are working together for a common cause. Bristol-Myers Squibb embodies that same sense of a common cause, explains Lynch. The common cause centers around the idea of scientists, regulatory agencies, and clinical trial developers working together to create better medicine, states Lynch.

Over the next several years, Lynch says that his goals are to improve the ability of these medicines to make a difference in improving the cure rate for cancers and help people live longer, he says.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD